Transplantation Drug Development Pipeline Review, 2017

Transplantation Drug Development Pipeline Review, 2017

  • July 2017 •
  • Report ID: 4978349 •
  • Format: PDF
Transplantation Drug Development Pipeline Review, 2017

Summary

This report provides an overview of the transplantation pipeline landscape, specifically covering drugs used to prevent and treat organ rejection and graft-versus-host disease. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for graft-versus-host disease (GVHD), and the rejection of bone, liver, kidney, lung and heart transplants.

Bone marrow transplant rejection is a complication that can occur after a stem cell or bone marrow transplant. The newly transplanted donor cells attack the transplant recipient’s body. There are a total of 121 products in development for this indication, by 83 companies and 21 academic institutions. Key companies operating in this pipeline space include Novartis and Abbvie.

GVHD is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient’s body. There are a total of 108 products in development for this indication, by 76 companies and 19 academic institutions. Similarly to the bone marrow transplantation space, key companies operating in this pipeline space include Novartis and Abbvie.

Following a liver transplant, the immune system may consider the transplanted liver as foreign and may work against it. Patients may hence develop complications and ultimately reject the new organ. There are a total of ten products in development for this indication, by seven companies and two academic institutions.

Kidney transplantation is a therapy performed to replace a diseased kidney with a healthy kidney from another person. Risk factors associated with transplantation are bleeding, infection, blockage of the blood vessels to the new kidney, leakage of urine or blockage of urine in the ureter and initial lack of function of the new kidney. There are a total of 39 products in development for this indication, by 33 companies and two academic institutions. Key companies operating in this pipeline space include Astellas, GlaxoSmithKline, Hillhurst Biopharmaceuticals and Kyowa Hakko Kirin.

Lung transplantation is a therapy used in various lung diseases. Lung transplant replaces an injured or diseased lung with a healthy one. Risk factors associated with transplantation are bleeding, infection, clots, and cardiovascular disorders. Following a transplant, the immune system may consider the transplanted lung as foreign and may work against it. There are a total of ten products in development for this indication, by eight companies. Key companies operating in this pipeline space include Quark Pharmaceuticals and Radikal Therapeutics, both of which are fielding two products in this area each.

Finally, heart transplantation is a therapy used in various heart diseases. Heart transplant replaces an injured or diseased heart with a healthy one. Risk factors associated with transplantation are bleeding, infection, clots, and cardiovascular disorders. Following a transplant, the immune system may consider the transplanted heart as foreign and may work against it. There are a total of seven products in development for this indication, all of which are in the Preclinical stage, by five companies, Of these products, Astellas are fielding three.

A wide range of targets, including integrins, chemokine receptors, protein kinases and cadherins are being developed, with no particular class of target predominating in terms of pipeline volume. However, there is a clear trend towards immune system molecular targets being studied, reflecting the underlying immune-based pathophysiology of these indications.

Scope

- Which companies are the most active within the pipeline for transplantation therapeutics?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in the field of transplantation therapeutics?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.